IONTAS, a clinical research organisation (CRO) had identified novel human binders (antibody fragments) which target BiVictriX’s proprietary “twin cancer antigens”, a statement said.
BiVictriX is pioneering a pipeline of Bi-Cygni therapeutics, a revolutionary form of cancer treatment designed to selectively target antigen co-expression fingerprints, or “twin antigens”, on tumour cells thus avoiding damage to healthy cells.
The results will be further assessed in-house by BiVictriX to validate the efficacy and selectivity in human cell models.
Tiffany Thorn, BiVictriX’s chief executive, added: “The delivery of these novel binders with species cross-reactivity is an important step for the team and our pipeline and a testament to our successful and ongoing collaboration with IONTAS.”
BVX001 is in preclinical development for Acute Myeloid leukaemia, one of the most aggressive forms of blood cancer.
Separately, BiVictriX, which is at a very early stage of development, reported results for the six months to June 2021 showing a loss of GBP451,000 after R&D spending of GBP165,000.
In August, the group listed on AIM and raised GBP7.5mln gross to fund its development programmes.